Analyst Price Targets — IMNM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 12, 2026 11:05 am | — | H.C. Wainwright | $40.00 | $23.41 | TheFly | Immunome initiated with a Buy at H.C. Wainwright |
| December 16, 2025 1:41 pm | — | Lake Street | $32.00 | $23.39 | TheFly | Immunome price target raised to $32 from $22 at Lake Street |
| December 16, 2025 1:06 pm | — | Evercore ISI | $40.00 | $23.35 | TheFly | Immunome price target raised to $40 from $18 at Evercore ISI |
| December 15, 2025 8:05 pm | — | Leerink Partners | $40.00 | $22.65 | TheFly | Immunome price target raised to $40 from $38 at Leerink |
| December 1, 2025 12:08 pm | Karina Rabayeva | Truist Financial | $36.00 | $18.42 | TheFly | Immunome initiated with a Buy at Truist |
| November 17, 2025 12:08 pm | — | Stephens | $33.00 | $17.14 | StreetInsider | Immunome Inc. (IMNM) PT Raised to $33 at StephensMember Login |
| September 5, 2025 11:46 am | — | Craig-Hallum | $26.00 | $10.52 | TheFly | Immunome initiated with a Buy at Craig-Hallum |
| August 22, 2025 10:16 am | — | Evercore ISI | $18.00 | $10.30 | TheFly | Immunome initiated with an Outperform at Evercore ISI |
| August 13, 2024 6:42 am | Biren Amin | Piper Sandler | $23.00 | $12.64 | TheFly | Immunome price target lowered to $23 from $27 at Piper Sandler |
| April 15, 2024 6:14 am | Michael Schmidt | Guggenheim | $35.00 | $20.58 | TheFly | Immunome initiated with a Buy at Guggenheim |
Latest News for IMNM
Immunome stock shows renewed strength after a pennant breakout, signaling a potential continuation of its recovery trend with upside momentum building toward prior highs.
Immunome, Inc. (NASDAQ: IMNM - Get Free Report) CFO Max Rosett sold 65,000 shares of Immunome stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $21.92, for a total value of $1,424,800.00. Following the sale, the chief financial officer directly owned 54,037 shares in the company,
9,438 shares were sold for a transaction value of ~$204,000 on April 2, 2026. This sale represented 30.02% of Higgins's holdings at the time.
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of…
Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMNM.
U.S. House Trading
No House trades found for IMNM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.